Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 5.03
NAS:ZGNX's Cash to Debt is ranked higher than
57% of the 790 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.44 vs. NAS:ZGNX: 5.03 )
Ranked among companies with meaningful Cash to Debt only.
NAS:ZGNX' s Cash to Debt Range Over the Past 10 Years
Min: 0.29  Med: 1.79 Max: N/A
Current: 5.03
Equity to Asset 0.56
NAS:ZGNX's Equity to Asset is ranked lower than
60% of the 724 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. NAS:ZGNX: 0.56 )
Ranked among companies with meaningful Equity to Asset only.
NAS:ZGNX' s Equity to Asset Range Over the Past 10 Years
Min: -3.87  Med: 0.17 Max: 0.61
Current: 0.56
-3.87
0.61
F-Score: 2
Z-Score: -1.07
M-Score: -1.11
WACC vs ROIC
16.66%
-113.83%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -265.12
NAS:ZGNX's Operating margin (%) is ranked lower than
91% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.64 vs. NAS:ZGNX: -265.12 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:ZGNX' s Operating margin (%) Range Over the Past 10 Years
Min: -299.29  Med: -155.85 Max: 142.89
Current: -265.12
-299.29
142.89
Net-margin (%) -229.93
NAS:ZGNX's Net-margin (%) is ranked lower than
91% of the 737 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.21 vs. NAS:ZGNX: -229.93 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:ZGNX' s Net-margin (%) Range Over the Past 10 Years
Min: -313.81  Med: -165.1 Max: 96.18
Current: -229.93
-313.81
96.18
ROE (%) -32.57
NAS:ZGNX's ROE (%) is ranked lower than
84% of the 763 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.92 vs. NAS:ZGNX: -32.57 )
Ranked among companies with meaningful ROE (%) only.
NAS:ZGNX' s ROE (%) Range Over the Past 10 Years
Min: -491.54  Med: -398.45 Max: 23.3
Current: -32.57
-491.54
23.3
ROA (%) -19.10
NAS:ZGNX's ROA (%) is ranked lower than
81% of the 798 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. NAS:ZGNX: -19.10 )
Ranked among companies with meaningful ROA (%) only.
NAS:ZGNX' s ROA (%) Range Over the Past 10 Years
Min: -164.96  Med: -84.9 Max: 10.28
Current: -19.1
-164.96
10.28
ROC (Joel Greenblatt) (%) -359.74
NAS:ZGNX's ROC (Joel Greenblatt) (%) is ranked lower than
87% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.01 vs. NAS:ZGNX: -359.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:ZGNX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -508.05  Med: -356.62 Max: 350.09
Current: -359.74
-508.05
350.09
Revenue Growth (3Y)(%) -34.00
NAS:ZGNX's Revenue Growth (3Y)(%) is ranked lower than
94% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.50 vs. NAS:ZGNX: -34.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:ZGNX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -62.2 Max: -34
Current: -34
EBITDA Growth (3Y)(%) -15.20
NAS:ZGNX's EBITDA Growth (3Y)(%) is ranked lower than
85% of the 575 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.50 vs. NAS:ZGNX: -15.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:ZGNX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -73.05 Max: -15.2
Current: -15.2
EPS Growth (3Y)(%) -25.60
NAS:ZGNX's EPS Growth (3Y)(%) is ranked lower than
85% of the 539 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.30 vs. NAS:ZGNX: -25.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:ZGNX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -71.05 Max: -25.6
Current: -25.6
GuruFocus has detected 4 Warning Signs with Zogenix Inc $NAS:ZGNX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ZGNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ZGNX Guru Trades in Q1 2016

Paul Tudor Jones 16,400 sh (-1.28%)
Jim Simons 74,087 sh (-45.88%)
» More
Q2 2016

ZGNX Guru Trades in Q2 2016

Paul Tudor Jones Sold Out
Jim Simons 37,187 sh (-49.81%)
» More
Q3 2016

ZGNX Guru Trades in Q3 2016

Jim Simons 93,287 sh (+150.86%)
» More
Q4 2016

ZGNX Guru Trades in Q4 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ZGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NAS:NBRV, OTCPK:AGYTF, NAS:RMTI, NAS:ASMB, NAS:OASM, NAS:ALIM, OTCPK:BIOYF, AMEX:NNVC, AMEX:AXN, NAS:PRPH, NAS:NVGN, NAS:IMNP, OTCPK:SUWN, OTCPK:CHEXF, NAS:TNXP, OTCPK:INNV, NAS:ALQA, AMEX:CPHI, NAS:BSPM, OTCPK:INBP » details
Traded in other countries:Z081.Germany,
Zogenix Inc is a pharmaceutical company engaged in commercializing & developing therapies that address clinical needs for people living with pain-related and CNS disorders that needs treatment alternatives to help return to normal daily functioning.

Zogenix Inc was formed as a Delaware Corporation on May 11, 2006. The Company is a pharmaceutical company that develops and commercializes therapies that address specific needs for people living with pain-related conditions and central nervous system disorders who needs treatment alternatives to help them return to normal daily functioning. The Company's first commercial product, Sumavel DosePro Needle-free Delivery System, was launched in January 2010. Sumavel DosePro offers fast-acting, easy-to-use, needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache in a pre-filled, single-use delivery system. Sumavel DosePro is the first drug product approved by the U.S. Food and Drug Administration, or FDA that allows for the needle-free, subcutaneous delivery of medication. Sumavel DosePro may offer a faster-acting and more efficacious treatment alternative to oral and nasal triptans and simple, convenient administration when compared to traditional, needle-based sumatriptan injection. The Company's main product candidate, Zohydro ER, is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternate treatment options are inadequate. The Company also develops Relday, a proprietary, long-acting injectable formulation of risperidone using Durect Corporation's SABER controlled-release formulation technology through a development and license agreement with Durect Corporation. The Company's competitors include: AstraZeneca plc, Endo Pharmaceuticals Holdings Inc., Johnson & Johnson, Merck & Co., and Pfizer, Inc. In the United States, pharmaceutical products are subject to extensive regulation by the FDA. Its trademarks include DosePro, Relday, Zogenix and Zohydro ER. The Company is subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or FFDCA, and other federal and state statutes and regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.

Ratios

vs
industry
vs
history
P/B 1.82
ZGNX's P/B is ranked higher than
71% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.02 vs. ZGNX: 1.82 )
Ranked among companies with meaningful P/B only.
ZGNX' s P/B Range Over the Past 10 Years
Min: 1.15  Med: 4.04 Max: 543.53
Current: 1.82
1.15
543.53
P/S 10.45
ZGNX's P/S is ranked lower than
79% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.06 vs. ZGNX: 10.45 )
Ranked among companies with meaningful P/S only.
ZGNX' s P/S Range Over the Past 10 Years
Min: 0.3  Med: 5.66 Max: 14.79
Current: 10.45
0.3
14.79
Current Ratio 9.58
ZGNX's Current Ratio is ranked higher than
90% of the 726 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. ZGNX: 9.58 )
Ranked among companies with meaningful Current Ratio only.
ZGNX' s Current Ratio Range Over the Past 10 Years
Min: 0.85  Med: 1.76 Max: 10.58
Current: 9.58
0.85
10.58
Quick Ratio 8.91
ZGNX's Quick Ratio is ranked higher than
90% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. ZGNX: 8.91 )
Ranked among companies with meaningful Quick Ratio only.
ZGNX' s Quick Ratio Range Over the Past 10 Years
Min: 0.32  Med: 1.47 Max: 9.74
Current: 8.91
0.32
9.74
Days Inventory 180.92
ZGNX's Days Inventory is ranked lower than
77% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.19 vs. ZGNX: 180.92 )
Ranked among companies with meaningful Days Inventory only.
ZGNX' s Days Inventory Range Over the Past 10 Years
Min: 180.92  Med: 226.42 Max: 419.33
Current: 180.92
180.92
419.33
Days Sales Outstanding 99.45
ZGNX's Days Sales Outstanding is ranked lower than
68% of the 628 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.32 vs. ZGNX: 99.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
ZGNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 18.75  Med: 58.69 Max: 99.45
Current: 99.45
18.75
99.45
Days Payable 52.93
ZGNX's Days Payable is ranked lower than
65% of the 574 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.12 vs. ZGNX: 52.93 )
Ranked among companies with meaningful Days Payable only.
ZGNX' s Days Payable Range Over the Past 10 Years
Min: 52.93  Med: 85.38 Max: 148.78
Current: 52.93
52.93
148.78

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -25.30
ZGNX's 3-Year Average Share Buyback Ratio is ranked lower than
85% of the 436 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. ZGNX: -25.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ZGNX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -348.1  Med: -32.9 Max: 0
Current: -25.3
-348.1
0

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 12.21
ZGNX's Price/Net Current Asset Value is ranked lower than
68% of the 542 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ZGNX: 12.21 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ZGNX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.95  Med: 5.71 Max: 22.24
Current: 12.21
3.95
22.24
Price/Tangible Book 7.84
ZGNX's Price/Tangible Book is ranked lower than
76% of the 747 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.65 vs. ZGNX: 7.84 )
Ranked among companies with meaningful Price/Tangible Book only.
ZGNX' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.82  Med: 7.63 Max: 470.59
Current: 7.84
2.82
470.59
Price/Median PS Value 1.85
ZGNX's Price/Median PS Value is ranked lower than
79% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. ZGNX: 1.85 )
Ranked among companies with meaningful Price/Median PS Value only.
ZGNX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.08  Med: 0.93 Max: 2.01
Current: 1.85
0.08
2.01
Earnings Yield (Greenblatt) (%) -36.84
ZGNX's Earnings Yield (Greenblatt) (%) is ranked lower than
93% of the 835 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. ZGNX: -36.84 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ZGNX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -38.5  Med: 34.3 Max: 20885.8
Current: -36.84
-38.5
20885.8

More Statistics

Revenue (TTM) (Mil) $23.95
EPS (TTM) $ -2.37
Beta1.96
Short Percentage of Float20.70%
52-Week Range $7.33 - 13.70
Shares Outstanding (Mil)24.79

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 24 24 34 61
EPS ($) -2.37 -2.88 -4.79 -1.37
EPS w/o NRI ($) -2.37 -2.88 -4.79 -1.37
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:ZGNX

Headlines

Articles On GuruFocus.com
Analysts Weigh in on Zogenix in Light of Selling Zohydro Mar 12 2015 
Weekly CFO Buys Highlight: NGL, UNTK, ZGNX, VTSS, RVSB Dec 24 2012 
(ZGNX) CEO Roger Hawley buys 10,000 Shares Dec 06 2010 

More From Other Websites
Zogenix to Participate in the 2017 RBC Capital Markets Healthcare Conference Feb 15 2017
Zogenix Announces Initiation of Clinical Efficacy Portion of Study 1504 for ZX008 in Dravet Syndrome Feb 13 2017
Zogenix to Participate in the Leerink Partners 6th Annual Global Healthcare Conference Feb 08 2017
ZOGENIX, INC. Files SEC form 8-K, Other Events Jan 30 2017
Zogenix Announces Issuance of U.S. Patent for ZX008 in Dravet Syndrome Jan 30 2017
Blog Coverage Novartis Announced Buyback of Shares Worth $5 Billion; Considers Strategic Options for... Jan 26 2017
ZOGENIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jan 09 2017
Zogenix Announces CFO Transition Jan 05 2017
ZOGENIX, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jan 05 2017
Zogenix Announces CFO Transition Jan 05 2017
ETFs with exposure to Zogenix, Inc. : December 21, 2016 Dec 21 2016
Is Foamix Pharmaceuticals Ltd (FOMX) Going to Burn These Hedge Funds? Dec 09 2016
ZOGENIX, INC. Files SEC form 8-K, Other Events Dec 05 2016
Zogenix Announces New Efficacy and Safety Data for ZX008 in Treatment of Seizures in Lennox Gastaut... Dec 05 2016
Hedge Funds Are Piling Back Into Zogenix, Inc. (ZGNX): Should You Follow? Dec 02 2016
Earnings Estimates Moving Higher for Zogenix (ZGNX): Time to Buy? Nov 30 2016
Moving Average Crossover Alert: Zogenix (ZGNX) Nov 23 2016
New Data on Zogenix’s ZX008 for Lennox Gastaut Syndrome & Dravet Syndrome to be Presented at 70th... Nov 22 2016
Zogenix to Participate in Oppenheimer Life Sciences Summit 2016 Nov 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)